Endocrinol Metab.  2025 Feb;40(1):70-72. 10.3803/EnM.2025.2333.

Treatment of Graves’ Disease: Faster Remission or Longer but Safe, That Is the Question

• Jung CH

• KMID: 2565254
• DOI: http://doi.org/10.3803/EnM.2025.2333

Reference

1. Wiersinga WM. Graves’ disease: can it be cured? Endocrinol Metab (Seoul). 2019; 34:29–38.

2. Parameswaran R, de Jong MC, Kit JL, Sek K, Nam TQ, Thang TV, et al. 2021 Asia-Pacific Graves’ disease consortium survey of clinical practice patterns in the management of Graves’ disease. Endocrine. 2023; 79:135–42.

3. Bandai S, Okamura K, Fujikawa M, Sato K, Ikenoue H, Kitazono T. The long-term follow-up of patients with thionamide-treated Graves’ hyperthyroidism. Endocr J. 2019; 66:535–45.

4. Park SY, Kim BH, Kim M, Hong AR, Park J, Park H, et al. The longer the antithyroid drug is used, the lower the relapse rate in Graves’ disease: a retrospective multicenter cohort study in Korea. Endocrine. 2021; 74:120–7.

5. Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, et al. Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid. 2019; 29:1192–200.

6. Azizi F. Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid. 2020; 30:1451–7.

7. El Kawkgi OM, Ross DS, Stan MN. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves’ disease: a review of the literature. Clin Endocrinol (Oxf). 2021; 95:3–12.

8. Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, et al. The second antithyroid drug treatment is effective in relapsed Graves’ disease patients: a median 11-year followup study. Thyroid. 2017; 27:491–6.

9. Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association. Endocrinol Metab (Seoul). 2013; 28:275–9.

10. Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012; 33:920–80.

11. Villagelin D, Cooper DS, Burch HB. A 2023 international survey of clinical practice patterns in the management of Graves disease: a decade of change. J Clin Endocrinol Metab. 2024; 109:2956–66.

12. Kim JA, Kim KJ, Choi J, Kim KJ, Song E, Yu JH, et al. Unveiling risk factors for treatment failure in patients with Graves’ disease: a nationwide cohort study in Korea. Endocrinol Metab. 2025; 40:125–34.

13. Rosenthal MS. Patient misconceptions and ethical challenges in radioactive iodine scanning and therapy. J Nucl Med Technol. 2006; 34:143–52.

14. Ma EZ, Kuo JH, Malek R, Turner DJ, Olson JA, Slejko JF, et al. Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves’ disease. Surgery. 2023; 173:193–200.

15. Salman MA, Assal MM, Salman A, Elsherbiney M. Outcomes of radioactive iodine versus surgery for the treatment of graves’ disease: a systematic review and meta-analysis. Indian J Surg. 2024; 86:18–26.

16. Engelbrecht-Wiggans EA, Carlisle K, Yunasan E, Fan C, Munir KM, Terhune J, et al. Long-term retreatment outcomes after definitive management of Graves’ disease with radioactive iodine versus surgery. Surgery. 2025; 177:108828.

17. Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan I, et al. Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019; 7:278–87.

18. Ryodi E, Metso S, Huhtala H, Valimaki M, Auvinen A, Jaatinen P. Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy. Thyroid. 2018; 28:1111–20.

19. Naser JA, Pislaru SV, Stan MN, Lin G. Incidence, risk factors, and outcomes of incident atrial fibrillation in patients with Graves disease. Mayo Clin Proc. 2023; 98:883–91.

20. Cho YY, Kim B, Choi D, Kim CH, Shin DW, Kim JS, et al. Graves’ disease, its treatments, and the risk of atrial fibrillation: a Korean population-based study. Front Endocrinol (Lausanne). 2022; 13:1032764.

21. Song E, Kim M, Park S, Park MJ, Kim JA, Roh E, et al. Treatment modality and risk of heart failure in patients with long-standing Graves’ disease: a nationwide population-based cohort study. Front Endocrinol (Lausanne). 2021; 12:761782.

22. Issa PP, Hussein M, Omar M, Munshi R, Attia AS, Buti Y, et al. Cardiovascular health by Graves’ disease management modality: surgery versus radioactive iodine versus antithyroid medications: a network meta-analysis. J Surg Res. 2023; 283:266–73.

23. Peng CC, Lin YJ, Lee SY, Lin SM, Han C, Loh CH, et al. MACE and hyperthyroidism treated with medication, radioactive iodine, or thyroidectomy. JAMA Netw Open. 2024; 7:e240904.

24. Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. J Endocrinol. 2012; 213:209–21.